PUBLIC COMPANY
save$CABACabaletta Bio, Inc.
$CABAPhiladelphia, PA, USupdated 2mo ago
community read0 votes
pipeline
4
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Preclinical1Phase 11Phase 21Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study haltsWall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.biopharma_dive · 1mo ago
- Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety eventsNovartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases of immune effector cell-associated hemophagocytic syndrome. BMS, meanwhil…biospace · 1mo ago
- UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studiesThree deaths have forced Novartis to pause development of its CD19 CAR-T candidate in autoimmune diseases, just as Bristol Myers Squibb has halted a similar program due to immune-related adverse ev…fiercebiotech · 1mo ago
- CAR Ts will only treat autoimmune diseases if we can scale deliveryBiopharmas developing CAR T therapies for autoimmune indications face major barriers to maximizing the market. Advances in the provider ecosystem and clinical infrastructure, as well as access and…biospace · 1mo ago
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that